Direct ELISA, Biotin-labelled antibody
Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).
Limit of Detection
n = 8; CV = 1,9%
n = 6; CV = 5,4%
Bone and cartilage metabolism, Diabetology - Other Relevant Products, Energy metabolism and body weight regulation
Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1, PC-1) is a class II transmembrane glycoprotein that is located both on the plasma membrane and in the endoplasmatic reticulum. Human ENPP1 belongs to the ectonucleotide pyrophosphatase/phosphodiesterase (ENPP) family of proteins which hydrolyze pyrophosphate or phosphodiester bonds in various extracellular compounds, such as nucleotides and lysophospholipids. These proteins consist of a short terminal NH2 intracellular domain, a single transmembrane domain, two somatomedin-B-like domains and COOH-terminal nuclease-like domain.
ENPP1 is a 230-260 kDa homodimer, and its reduced form has a molecular size of 115-135 kDa depending on the cell type. Human ENPP1 has 873 amino acids and its gene is located on the long arm of chromosome 6 (6q23.2).
ENPP1 is expressed in various tissues including liver, skeletal muscle and adipose tissue. It is also expressed in heart, brain, kidney, placenta, pancreatic islets, kidney, lung, chondrocytes, lymphocytes, and dermal fibroblasts.
The physiological function of ENPP1 is not completely understood. There is evidence that ENPP1 plays a major role in bone and cartilage metabolism by producing pyrophosphate. The latter substance inhibits bone formation. In ENPP1 knockout mice and in humans lacking ENPP1 there is ectopic calcification in the spine, aorta, and other tissues with markedly decreased survival. ENPP1 seems to play a role in glucose metabolism impairment in vivo. Insulin resistant rodents and humans show high levels of expression of this protein. Several studies reported that mutations in the ENPP1 gene are associated with idiopathic infantile arterial calcification, ossification of the posterior longitudinal ligament of the spine (OPLL) and insulin resistance.